Evidence map›Paper›PMID 23874084›Full record

ArticleDrug design, development and therapy2013

Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration.

Georgios D Panos, Zisis Gatzioufas, Ioannis K Petropoulos, Doukas Dardabounis, Gabriele Thumann, Farhad Hafezi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017
    Article
  9. Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment.Medical science monitor : international medical journal of experimental and clinical research · 2016
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Ranibizumab for the treatment of degenerative ocular conditions.Clinical ophthalmology (Auckland, N.Z.) · 2014
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Georgios D PanosDepartment of Ophthalmology, Geneva University Hospitals and Faculty of Medicine of the University of Geneva, Switzerland. georgios.panos@hcuge.ch
Zisis Gatzioufas
Ioannis K Petropoulos
Doukas Dardabounis
Gabriele Thumann
Farhad Hafezi

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo report the effect of intravitreal ranibizumab therapy for serous and vascular pigment epithelial detachments (PED) associated with choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD).

methodsIn a prospective study, best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) data were collected for 62 eyes of 62 patients, with serous or vascular PED associated with CNV secondary to AMD. Intravitreal ranibizumab 0.5 mg was administered with a loading phase of three consecutive monthly injections, followed by monthly review with further treatment, as indicated according to the retreatment criteria of the PrONTO study. The change in visual acuity and PED height from baseline to month 12 after the first injection was determined.

resultsSixty-one eyes of 61 patients (one of the patients developed retinal pigment epithelial tear and was excluded from the study) were assessed at the 12-month follow-up examination. There were two types of PED, including vascular PED in 32 patients (Group A) and serous PED (Group B) in 29 patients. The mean improvement of mean BCVA from baseline to 12 months was 0.09 logMAR (Logarithm of the Minimum Angle of Resolution) in Group A and 0.13 logMAR in Group B. Both groups showed significant improvement of the mean BCVA 12 months after the first injection compared with the baseline value (P < 0.05). In relation to the PED height, the mean decrease of mean PED height from baseline to 12 months was 135 μm in Group A and 180 μm in Group B. Both groups showed significant reduction of the PED height during the follow-up period (P < 0.01). The PED anatomical response to ranibizumab was not correlated with the BCVA improvement in any of the groups. Apart from one patient who developed pigment epithelial tear no other complications were documented.

conclusionRanibizumab is an effective and safe treatment for improving vision in patients with serous and vascular PED, although the anatomical response of the PED to ranibizumab may not correlate directly with the visual outcome.

Indexed as

AgedAged, 80 and overAntibodies, Monoclonal, HumanizedChoroidal NeovascularizationFemaleHumansMacular DegenerationMaleMiddle AgedProspective StudiesRanibizumabRetinal DetachmentRetinal Pigment EpitheliumTomography, Optical CoherenceVisual AcuityAntibodies, Monoclonal, HumanizedRanibizumabage-related macular degenerationchoroidal neovascularisationintravitreal injectionpigment epithelial detachmentranibizumab

Identifiers

PMID23874084
PMCPMC3712738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.